Nkarta Inc
nkartatx.comNkarta Inc (NASDAQ: NKTX) is a clinical-stage cell therapy company that engineers natural killer (NK) cells derived from healthy donors to treat cancer and autoimmune diseases. The company generates no product revenue, funding operations through equity capital while advancing a pipeline of chimeric antigen receptor NK (CAR NK) cell therapy candidates. Nkarta's lead program, NKX019, is in Phase 1 clinical trials for autoimmune indications including lupus nephritis and primary membranous nephropathy, evaluated in the Ntrust-1 and Ntrust-2 multi-center, open-label, dose-escalation studies. The company's engineering platform adds a targeting CAR, OX40 costimulatory domain, CD3-zeta signaling moiety, and a membrane-bound form of IL-15 to donor-derived NK cells. In March 2025, Nkarta approved a workforce reduction to cut costs and streamline operations around its reprioritized pipeline. General and administrative expenses were $31.6 million for the year ended December 31, 2025, roughly flat versus $31.5 million for the year ended December 31, 2024. The company operates out of facilities leased from HCP Life Science REIT.
Products & Services
NKX019: CAR NK cell therapy candidate in Phase 1 trials for lupus nephritis and primary membranous nephropathy (Ntrust-1 and Ntrust-2, as of the 10-K filed 2026-03-25). NKX101: a previously advanced program that was deprioritized as of FY2025. The engineering platform uses donor-derived mature NK cells modified with a CAR, OX40 costimulatory domain, CD3-zeta signaling, and membrane-bound IL-15.
Revenue Model
Pre-revenue clinical-stage company. No product sales. Operations are funded through equity capital raises. All spending is directed toward research and development, including manufacturing, clinical trials, and preclinical work.
Customers & Markets
No commercial customers as of the 10-K filed 2026-03-25. Target end markets are autoimmune diseases (lupus nephritis, primary membranous nephropathy) and, based on prior pipeline activity, oncology. End customers, if products reach approval, would be patients and healthcare providers, with reimbursement dependent on government and private payors.
Geographic Exposure
Operations are based in the United States, with facilities leased in the life science real estate portfolio of HCP Life Science REIT. Clinical trials are conducted at multiple centers. No international commercial operations are disclosed in the filing excerpts.
Financial Snapshot
Loading...
